Submitted by Anonymous (not verified) on 28 January 2026 - 16:10
Human medicines European public assessment report (EPAR): Saphnelo, anifrolumab, Date of authorisation: 14/02/2022, Revision: 9, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Saphnelo, anifrolumab, Date of authorisation: 14/02/2022, Revision: 9, Status: Authorised